Ion-pair solid phase extraction for the simultaneous separation and quantitation of metformin and canagliflozin in human plasma by LC-MS/MS

被引:21
作者
Shah, Priyanka A. [1 ]
Shrivastav, Pranav S. [1 ]
机构
[1] Gujarat Univ, Sch Sci, Dept Chem, Ahmadabad 380009, Gujarat, India
关键词
Metformin; Canagliflozin; Ion-pair solid phase extraction; Human plasma; LC-MS/MS; Pharmacokinetics; INTERACTION LIQUID-CHROMATOGRAPHY; GLUCOSE COTRANSPORTER 2; RAT PLASMA; MASS-SPECTROMETRY; COMBINATION; PHARMACOKINETICS; PHARMACODYNAMICS; PARTICIPANTS; VALIDATION; MANAGEMENT;
D O I
10.1016/j.microc.2018.08.005
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A high-throughput and sensitive liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) has been developed for the simultaneous determination of metformin and canagliflozin in human plasma. The optimized ion-pair solid phase extraction of the analytes was carried out using 100 mu L plasma, followed by reversed-phase chromatography on COSMOSIL 5CN-MS (150 x 4.6 mm, 5 mu m) column. An isocratic mobile phase consisting of methanol-20 mM ammonium formate in water, pH 5 (75:25, v/v) was used for separation of the analytes with a resolution factor of 2.18. Mass spectrometer was operated in the multiple reaction monitoring mode at unit mass resolution. Electro spray ionization was used for mass transition of m/z 130.1/60.1 and m/z 462.1/267.1 for metformin and canagliflozin, respectively. The method was successfully validated for the concentration range of 2.50-2500 ng/mL for both the analytes. The intra- and inter-batch precision determinations for metformin and canagliflozin, expressed as coefficient of variation were lower than 5.5% at all the test concentrations. Recovery of both the drugs was in the range of 78-90% and was reproducible in the quality control samples. No significant matrix effects were observed for the analytes as evident from the IS normalized matrix factors. Stability of the drugs in whole blood and plasma samples was ascertained under different conditions. The assay showed acceptable performance when applied to clinical samples generated from healthy Indian subjects.
引用
收藏
页码:181 / 189
页数:9
相关论文
共 31 条
[1]   Development and Validation of LC-MS/MS Method for Simultaneous Determination of Metformin and Four Gliptins in Human Plasma [J].
Al Bratty, Mohammed ;
Alhazmi, Hassan A. ;
Javed, Sadique Akhtar ;
Lalitha, Keddal G. ;
Asmari, Mufarreh ;
Woelker, Jessica ;
El Deeb, Sami .
CHROMATOGRAPHIA, 2017, 80 (06) :891-899
[2]   Salting-out assisted liquid-liquid extraction coupled with hydrophilic interaction chromatography for the determination of biguanides in biological and environmental samples [J].
Alshishani, Areas ;
Salhimi, Salizawati Muhamad ;
Saad, Bahruddin .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2018, 1073 :51-59
[3]  
[Anonymous], 1996, GUID IND ICH E6 GOOD
[4]  
[Anonymous], 2013, GUID IND BIOAN METH
[5]   SGLT2 inhibition - a novel strategy for diabetes treatment [J].
Chao, Edward C. ;
Henry, Robert R. .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (07) :551-559
[6]   Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects [J].
Chen, Xia ;
Hu, Pei ;
Vaccaro, Nicole ;
Polidori, David ;
Curtin, Christopher R. ;
Stieltjes, Hans ;
Sha, Sue ;
Weiner, Sveta ;
Devineni, Damayanthi .
CLINICAL THERAPEUTICS, 2015, 37 (07) :1483-1492
[7]   Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview [J].
Davidson, Jaime A. ;
Sloan, Lance .
ADVANCES IN THERAPY, 2017, 34 (01) :41-59
[8]  
Devineni D., 2014, J BIOEQUIV AVAIL, V6, P164, DOI [10.4172/jbb.1000199, DOI 10.4172/JBB.1000199]
[9]   Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants [J].
Devineni, Damayanthi ;
Polidori, David ;
Curtin, Christopher ;
Stieltjes, Hans ;
Tian, Hong ;
Wajs, Ewa .
CLINICAL THERAPEUTICS, 2016, 38 (01) :89-98
[10]   Canagliflozin: a novel treatment option for type 2 diabetes [J].
Dietrich, Eric ;
Powell, Jason ;
Taylor, James R. .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2013, 7 :1399-1408